Medicare AdvantageCoverageMedium impact
MA08.172, Lifileucel (Amtagvi™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Sep 3, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.172 for Lifileucel (Amtagvi™) has been reissued and will take effect on September 3, 2025. This is a pharmacy policy update that may affect coverage criteria, prior authorization requirements, or billing procedures for this cancer immunotherapy drug.
Action Required
By September 3, 2025: Review the complete policy MA08.172 at the provided URL to understand specific coverage changes for Lifileucel (Amtagvi™). Update prior authorization workflows and billing procedures as specified in the full policy. Notify providers who may prescribe this cancer immunotherapy about any new requirements.